Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Honeywell Launches AI In-Store Shopping Tech with Google Cloud
Honeywell has announced the launch of a new AI-powered retail solution created in partnership with Google Cloud and 66degrees. The platform uses Google Gemini and Google Cloud Vertex AI to enhance how customers shop inside physical stores. Designed for retailers across global markets, the solution helps shoppers quickly find products, compare alternatives, and receive suggestions when items are unavailable, making store visits smoother and more convenient.
Smartan Debuts AI Injury Prevention Platform at CES 2026
Smartan has introduced its AI-driven injury prevention and rehabilitation platform at CES 2026, marking a major step forward for the young Indian startup. The launch showcased a computer vision system that has already delivered a 42 percent drop in sports injuries during pilot programs across India. The platform reflects years of focused development aimed at making advanced biomechanical insights accessible beyond elite laboratories and into everyday training environments.
RYBREVANT Shows Durable Results in Hard-to-Treat Colorectal Cancer
Johnson & Johnson has shared new longer-term findings from the Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The data demonstrated encouraging anti-tumor activity, sustained responses over time, and low rates of treatment-related discontinuation. These results support the continued evaluation of this treatment approach in ongoing Phase 3 studies for first- and second-line colorectal cancer. The findings were presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in Abstract #166.
Diorasis Therapeutics Appoints Richard A. Kresch, to Board of Directors
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, announced the appointment of Richard A. Kresch, MD, to its Board of Directors.
Oxford Nanopore Wins UK, Europe Approval for First Diagnostic Device
Oxford Nanopore Technologies announces that the GridION Dx is now both CE and UKCA marked, making it the company’s first IVD device registered in the UK and Europe. The CE and UKCA certification confirms that GridION™ Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to sequencing-based diagnostics.
To share your insights, please write to us at sudipto@intentamplify.com
